)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Galenica
Galenica (GALE) investor relations material
Galenica Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary22 Oct, 2026
Executive summary
Jan–Sep 2026 net sales rose 5.7% to CHF 3,172.0m; growth excluding Labor Team was 2.7%.
Pharmacy growth, home care and Diagnostics supported sales, while Q3 wholesale momentum was constrained by ERP-related product restrictions.
Financial highlights
Products & Care net sales increased 10.9% to CHF 1,446.3m; Logistics & IT sales rose 2.7% to CHF 2,498.0m.
Services & Production net sales grew 5.8% to CHF 93.6m; excluding Bichsel pharmaceutical production closure, growth was 10.5%.
Outlook and guidance
FY 2026 sales growth guidance remains 5%–7%; adjusted EBIT growth guidance remains 6%–8%, excluding IAS 19, IFRS 16, IFRS 3 and one-off effects.
Adjusted EBIT growth corresponds to 9%–11% excluding prior-year one-off items; Bichsel production-division closure costs were expected mainly in H1 2026 and excluded from adjusted EBIT.
Q4 wholesale growth momentum is expected to improve following the successful ERP switchover.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Galenica
- Sales rose 4.4%; adjusted EBIT grew 5.5% excluding one-off items.GALE
H2 2023 - Strong H1 2026 growth, robust financials, and ambitious sustainability targets in Swiss healthcare.GALEInvestor presentation
- Net sales up 7.1% to CHF 2,136.5m, with strong pharmacy and home care growth.GALEQ2 2026
- Sales up 7.3% to CHF 1,409.7m, driven by pharmacy, wholesale, and diagnostics growth.GALEQ1 2026 TU
- Strong sales and EBIT growth, market leadership, and ambitious sustainability targets for 2026.GALEInvestor presentation
- Sales and EBIT grew, net profit declined, and a CHF 2.50 dividend is proposed.GALEH2 2025
- Net sales rose 5.5% to CHF 4,135.6 million in 2025, with all segments and EBIT up 10-12%.GALEQ4 2025 TU
- Sales up 2.6% with market share gains and guidance reaffirmed for a stronger H2.GALEH1 2024
- Strong sales and profit growth, digital expansion, and higher dividend proposed for 2024.GALEH2 2024
Next Galenica earnings date
Q4 2026 TU21 Jan, 2027
Galenica
Next Galenica earnings date
Q4 2026 TU21 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Galenica AG is a Swiss healthcare company that operates in the areas of pharmaceuticals, healthcare products, and logistics services. The company’s activities span the distribution and retail of pharmaceutical and health-related products, as well as the provision of pharmacy services through its network of pharmacies. Galenica also offers logistics and supply chain management solutions for healthcare providers, ensuring the efficient delivery of medical products. Additionally, the company provides health and beauty products, contributing to both the pharmaceutical and consumer health markets. The company is headquartered in Bern, Switzerland, and its shares are listed on the SIX.